MA46453A - Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha - Google Patents

Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha

Info

Publication number
MA46453A
MA46453A MA046453A MA46453A MA46453A MA 46453 A MA46453 A MA 46453A MA 046453 A MA046453 A MA 046453A MA 46453 A MA46453 A MA 46453A MA 46453 A MA46453 A MA 46453A
Authority
MA
Morocco
Prior art keywords
compounds useful
ifn alpha
response modulators
alpha response
imidazopyridazine compounds
Prior art date
Application number
MA046453A
Other languages
English (en)
French (fr)
Inventor
Michael E Mertzman
Steven H Spergel
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA46453A publication Critical patent/MA46453A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA046453A 2016-10-07 2017-10-02 Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha MA46453A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662405309P 2016-10-07 2016-10-07

Publications (1)

Publication Number Publication Date
MA46453A true MA46453A (fr) 2019-08-14

Family

ID=60117794

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046453A MA46453A (fr) 2016-10-07 2017-10-02 Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha

Country Status (8)

Country Link
US (1) US10836770B2 (enExample)
EP (1) EP3523305B1 (enExample)
JP (1) JP7097875B2 (enExample)
KR (1) KR102531036B1 (enExample)
CN (1) CN110036015B (enExample)
ES (1) ES2902995T3 (enExample)
MA (1) MA46453A (enExample)
WO (1) WO2018067432A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6557436B1 (ja) 2018-03-12 2019-08-07 アッヴィ・インコーポレイテッド チロシンキナーゼ2媒介性シグナル伝達の阻害剤
US11891400B2 (en) 2018-09-10 2024-02-06 Eli Lilly And Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
ES2945220T3 (es) * 2018-09-13 2023-06-29 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas
BR112021007679A2 (pt) 2018-10-22 2021-07-27 Esker Therapeutics, Inc inibidores de tyk2 e seus usos
JP2022509019A (ja) 2018-11-05 2022-01-20 シンジェンタ パーティシペーションズ アーゲー 殺有害生物的に活性なアゾール-アミド化合物
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
WO2020154474A1 (en) 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
ES2953140T3 (es) 2019-03-08 2023-11-08 Syngenta Crop Protection Ag Compuestos de azol-amida activos de manera plaguicida
WO2020188014A1 (en) 2019-03-20 2020-09-24 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
CN113597426A (zh) 2019-03-22 2021-11-02 先正达农作物保护股份公司 N-[1-(5-溴-2-嘧啶-2-基-1,2,4-三唑-3-基)乙基]-2-环丙基-6-(三氟甲基)吡啶-4-甲酰胺衍生物及相关的化合物作为杀昆虫剂
AU2019443366A1 (en) 2019-04-30 2021-12-02 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
AR121251A1 (es) 2020-02-12 2022-05-04 Lilly Co Eli Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022037694A1 (zh) * 2020-08-20 2022-02-24 轶诺(浙江)药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
JP2023541203A (ja) * 2020-09-16 2023-09-28 アルミス インコーポレイテッド Tyk2阻害剤およびその使用
CN117083268B (zh) 2021-03-16 2024-07-30 安锐生物医药科技(广州)有限公司 氨基杂芳基化合物和组合物
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CN116655636A (zh) * 2022-02-17 2023-08-29 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
JP5394404B2 (ja) * 2008-02-06 2014-01-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用な置換イミダゾピリダジン類
CN104394869A (zh) * 2011-10-20 2015-03-04 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
KR102782807B1 (ko) * 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물

Also Published As

Publication number Publication date
EP3523305B1 (en) 2021-12-08
US20190225620A1 (en) 2019-07-25
JP2019530699A (ja) 2019-10-24
JP7097875B2 (ja) 2022-07-08
CN110036015A (zh) 2019-07-19
EP3523305A1 (en) 2019-08-14
CN110036015B (zh) 2022-07-19
KR20190057132A (ko) 2019-05-27
WO2018067432A1 (en) 2018-04-12
ES2902995T3 (es) 2022-03-30
US10836770B2 (en) 2020-11-17
KR102531036B1 (ko) 2023-05-09

Similar Documents

Publication Publication Date Title
MA46453A (fr) Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha
IL286693A (en) Modulator compounds of the integrated stress pathway, compositions comprising same and uses thereof
EP3434676A4 (en) SUBSTITUTED PYRROLOPYRIMIDINE-CDK INHIBITORS, PHARMACEUTICAL COMPOSITION THEREFOR AND USE THEREOF
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
EP3411411A4 (en) BENZOPYRAZOL COMPOUNDS AND ANALOGUE THEREOF
BR112017025828A2 (pt) dispositivo de nó hospedeiro e métodos de uso com o mesmo.
MA46620A (fr) Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
HUE060182T2 (hu) Szomatosztatin modulátorok és azok felhasználása
EP3538071A4 (en) PHARMACEUTICAL COMPOUNDING METHODS AND SYSTEMS
EP3428171A4 (en) CONNECTION AND COLOR TRANSFORMATION FILM THEREWITH
EP3542358A4 (en) SYSTEM FOR MIXED REALITY WITH PRESENTATION WITH REDUCED PERFORMANCE
HUE060805T2 (hu) Piridinamin-piridon és pirimidinamin-piridon vegyületek
EP3467033A4 (en) POLYCARBONATE COMPOSITION AND ARTICLES THEREWITH
EP3353533A4 (en) QUANTUM POINT SAFETY INKS
EP3528813A4 (en) P2X3 AND / OR P2X2 / 3 CONNECTIONS AND METHOD
EP3450444A4 (en) CROCINE COMPOUNDS AND USES THEREOF
FI20165030A7 (fi) Fluidikiertojärjestelmä kryokabiinikokoonpanoa varten ja vastaava kryokabiinikokoonpano
EP3328912A4 (en) POLYURETHANE (METH) ACRYLATOLIGOMERS AND HARDENABLE COMPOSITIONS USING THESE OLIGOMERS
MA44772A (fr) 6-aminopyridine-3-yl thiazoles utilisés en tant que modulateurs de ror t
EP3328368A4 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITION RELATING TO THE UBIQUITINATION PROTEASOM SYSTEM
EP3321535A4 (en) DISC BRAKE DEVICE
EP3347884A4 (en) PRIVACY-MAINTENANCE MONITORING
EP3521372A4 (en) HARDENABLE CHINONE COMPOSITIONS AND ADHESIVE COMPOSITIONS THEREFOR
EP3453705A4 (en) PHOTOISOMERE CONNECTIONS AND DEVICE THEREFOR
EP3481553A4 (en) MICROTITER PLATE AND USES THEREOF